Rite Aid is partnering with Apriss Health, which provides the Narxcare opioid stewardship and substance use disorder analytics platform NarxCare to help its pharmacists manage patients at risk of controlled substance abuse and misuse. Rite Aid has implemented NarxCare in 12 states, deploying it directly into pharmacists’ clinical workflow.
NarxCare accesses, analyzes and shares information with pharmacists from state prescription drug monitoring programs, or PDMPs, to make it easier for pharmacists to identify which patients might be at risk of medication abuse or misuse. These insights, now accessed directly within Rite Aid’s pharmacy workflow, are provided in a visually interactive format. NarxCare also uses machine learning and artificial intelligence to asses patient risk.
“NarxCare is another efficient and effective solution to help our pharmacists make responsible dispensing decisions, while mitigating possible controlled substance misuse or abuse,” said Jocelyn Konrad, executive vice president, pharmacy and retail operations, Rite Aid. “The integration of NarxCare and PDMP information into our pharmacist’s workflow empowers them to focus more on building relationships with patients and improving health and wellness across the communities they serve.”
NarxCare is meant to steamline the process of navigating and analyzing PDMP data for every customer in real-time.
“At Rite Aid, patient safety and compliance are important priorities,” said Rob Cohen, President, Appriss Health. “We applaud Rite Aid’s efforts to rapidly deploy technologies to help reduce potential customer risk by leveraging the state PDMPs, utilizing an advanced analytics platform, and integrating these solutions seamlessly into their pharmacists’ daily workflow.”